Aridis Pharmaceuticals
San Jose, US · Delaware corporation
Aridis Pharmaceuticals is a late-stage clinical biopharmaceutical company developing monoclonal antibody and small-molecule anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline targets antimicrobial-resistant bacteria and viral pandemics, using a platform that discovers human monoclonal antibodies from convalescent patients.
Founders & leadership
VT
Vu TruongChief Executive Officer and Chief Scientific Officer
FK
Fred KurlandChief Financial Officer
PD
Paul-Andre de LameinChief Medical Officer
JB
John BorgesonChief Financial Officer (Acting)
Board
CG
Craig GibbsBoard director
EP
Eric PatzerChairman of the Board of Directors
RC
Robert CoughlinBoard director
JH
John HamiltonBoard director
Reported raises · per SEC filings
Form D private placements$56.6M disclosed across 7 rounds · 2014–2022
▶$4.8MraisedDec 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedDec 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric PatzerDirector
- Susan Windham-BannisterDirector
- John HamiltonDirector
- Fred KurlandExecutive Officer
- Robert RuffoloDirector
- Craig GibbsDirector
- Vu TruongExecutive Officer
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Susan Windham-BannisterDirector
- Robert Ruffolo, Jr.Director
- Fred KurlandExecutive Officer
- Eric PatzerExecutive Officer, Director
- John HamiltonDirector
- Craig GibbsDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedOct 2020 · 8 investors · PharmaceuticalsRule 506(b)
▶$8.4MraisedOct 2020 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric PatzerExecutive Officer, Director
- Mike NazakExecutive Officer
- Susan Windham-BannisterDirector
- John HamiltonDirector
- Robert Ruffolo, Jr.Director
- Vu TroungExecutive Officer, Director
- Craig GibbsDirector
- Offering amount
- $8.4M
- Amount sold
- $8.4M
- Sales commissions
- $590K
- Placement agents
- Arcadia Securities, LLC, Cantor Fitzgerald & Co.
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.6MraisedDec 2016 · 14 investors · PharmaceuticalsRule 506(b)
▶$13.6MraisedDec 2016 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Craig GibbsDirector
- Fred KurlandExecutive Officer
- Isaac BlechDirector
- John HamiltonDirector
- Robert CoughlinDirector
- Robert Ruffolo, Jr.Director
- Paul-Andre de LameExecutive Officer
- Vu TroungExecutive Officer, Director
- Eric PatzerExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $13.6M
- Minimum investment
- $25K
- Sales commissions
- $1.4M
- Placement agents
- Maxim Merchant Capital, a division of Maxim Group LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.2MraisedAug 2016 · 133 investors · PharmaceuticalsRule 506(b)
▶$15.2MraisedAug 2016 · 133 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert K. CoughlinDirector
- Fred KurlandExecutive Officer
- John HamiltonDirector
- Eric PatzerExecutive Officer, Director
- Vu TruongExecutive Officer, Director
- Robert R. Ruffolo, Jr.Director
- Isaac BlechDirector
- Craig GibbsDirector
- Paul-Andre de LameExecutive Officer
- Offering amount
- $40M
- Amount sold
- $15.2M
- Minimum investment
- $50K
- Sales commissions
- $1.5M
- Placement agents
- Maxim Merchant Capital, a division of Maxim Group LLC
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2015 · 6 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2015 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Craig GibbsDirector
- Eric PatzerDirector
- Robert CoughlinDirector
- Fred KurlandExecutive Officer
- Paul-Andre de LameExecutive Officer
- John HamiltonDirector
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedJul 2014 · 9 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedJul 2014 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Fred KurlandDirector
- John BorgesonExecutive Officer
- Eric PatzerDirector
- Robert CoughlinDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $250K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAdial Pharmaceuticals10 shared keywordsAdial Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and inflammatory disease, including AT177, a colon-targeted AhR agonist for ulcerative colitis, and AD04, a genetically targeted serotonin-3 receptor antagonist in Phase 3 trials for Alcohol Use Disorder. It is publicly listed on Nasdaq under the ticker ADIL.
ANI Pharmaceuticals7 shared keywordsANI Pharmaceuticals is a generic and specialty pharmaceutical company that develops, manufactures, and distributes prescription drugs across multiple therapeutic areas including generics, rare diseases, and established branded products.
Companies competing with Aridis Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aridis Pharmaceuticals do?
- Aridis Pharmaceuticals is a late-stage clinical biopharmaceutical company developing monoclonal antibody and small-molecule anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline targets antimicrobial-resistant bacteria and viral pandemics, using a platform that discovers human monoclonal antibodies from convalescent patients.
- Who founded Aridis Pharmaceuticals?
- Aridis Pharmaceuticals was founded by Vu Truong.
- How much funding has Aridis Pharmaceuticals raised?
- Aridis Pharmaceuticals has disclosed $56.6M raised across 7 rounds.
- Where is Aridis Pharmaceuticals headquartered?
- Aridis Pharmaceuticals is headquartered in San Jose, US.